Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May:58:37-40.
doi: 10.1016/j.pediatrneurol.2016.01.022. Epub 2016 Mar 8.

Predictors of Triptan Response in Pediatric Migraine

Hannah F Johnson  1 , Peter J Goadsby  2 , Amy A Gelfand  3
Affiliations

Predictors of Triptan Response in Pediatric Migraine

Hannah F Johnson et al. Pediatr Neurol. 2016 May.

Abstract

Background: Migraine is common in children and adolescents and can be disabling. Being able to predict which patients will respond to triptans based on their clinical phenotype would be helpful. Adult data suggest cranial autonomic symptoms and aura predict triptan response. This study examined clinical predictors of triptan response in pediatric migraineurs.

Methods: This chart review study included all patients less than 18 years old with migraine who were seen at the University of California, San Francisco Headache Center in 2014. Univariate χ(2) analyses were performed, followed by multivariate logistic regression modeling.

Results: Of 127 pediatric migraineurs, 70 (55%) had chronic migraine and 24 (19%) had aura. The majority (55%) had at least one cranial autonomic symptom. Of 65 with triptan outcome data, 47 (73%) benefitted from a triptan. In univariate analyses, triptan benefit was seen in 65% with chronic migraine versus 88% with episodic migraine (P = 0.048), 67% with aura versus 74% without (P = 0.66), and 70% with cranial autonomic symptom versus 74% without (P = 0.76). In a multivariate logistic regression model, chronic migraine, aura, and cranial autonomic symptom were not statistically significant predictors of triptan benefit: chronic migraine: 0.25 (0.06-1.04); aura: 0.65 (0.09-4.45); cranial autonomic symptom: 0.75 (0.22-2.52).

Conclusions: In univariate analysis, individuals with chronic migraine were less likely to benefit from triptans. In contrast to what has been documented in adults, cranial autonomic symptoms and aura did not predict triptan response, although our small sample size limited the study's power. Larger pediatric studies are needed, and future pediatric triptan trials should provide response rates stratified by clinical variables such as aura.

Keywords: aura; cranial autonomic symptoms; migraine; pediatrics; triptan.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Percentage of pediatric migraine patients who benefitted from triptans, stratified by clinical predictors
CAS=cranial autonomic symptoms, CM=chronic migraine, EM=episodic migraine
See this image and copyright information in PMC

References

    1. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia : an international journal of headache. 2010;30(9):1065–1072. - PubMed
    1. The International Classificatio of Headache Disorders, 3rd edition (beta version) Cephalalgia : an international journal of headache. 2013;33(9):629–808. - PubMed
    1. Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. Neurology. 2012;79(18):1881–1888. - PubMed
    1. Lipton RB, Manack A, Ricci JA, Chee E, Turkel CC, Winner P. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS) Headache. 2011;51(5):693–706. - PubMed
    1. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33(1):29–35. - PubMed